BHI Therapeutic Sciences is initiating FDA endorsed Investigator-led IND (Investigational New Drug) clinical study of an FDA-approved cell therapy (Hematopoietic Progenitor Cell (HPC), cord blood) for treatment of acute ischemic stroke in NJ. This prospective, open-label, single-center, exploratory clinical study is designed to characterize the safety and efficacy profile of HCP, cord blood, when administered by intravenous infusion and intrathecal injection, in subjects who have sustained an acute ischemic stroke. BHI Therapeutic Sciences is in the process of preparation of Investigator-led IND application to allow for initiation of a clinical study of an FDA-approved cell therapy (HPC, cord blood) for treatment of osteoarthritis. This prospective, open-label, single-center, exploratory clinical study will be designed to characterize the safety and efficacy profile of HCP, cord blood, when administered by intra-articular injection, in subjects with osteoarthritis.
Texas House Bill (HB 810) on stem cell therapy passed in the Texas state legislature and became law, allowing patients suffering from debilitating and incurable diseases to access innovative stem cell therapies and expanded clinical trials.
BHI Therapeutic Sciences is opening a stem cell treatment facility in Houston, having treated thousands of patients around the world with stem cell therapy.
BHI Therapeutic Sciences is bringing the miracle of life saving stem cell treatments to the world, and you can help. Thanks to new laws that allow anyone in the general public to invest in new and emerging companies, you can invest in BHI Therapeutic Sciences. Sign up here and be among the first to know of developments with stem cell therapy and the opening of our clinic in Texas.